Oct 25, 2022 | Featured, ICER, Uncategorized
On October 11, 2022, ICER released its draft evidence report, “Fezolinetant for Moderate to Severe Vasomotor Symptoms Associated with Menopause.” This document provides a framework for considering what aspects of ICER’s review are important to women and their...
Read more
Jun 23, 2022 | Featured, ICER
On June 14, 2022, ICER released its draft evidence report, “AMX0035 and Oral Edaravone for Amyotrophic Lateral Sclerosis.” This document provides a framework for considering which aspects of two potential treatments for Amyotrophic Lateral Sclerosis (ALS) are...
Read more
May 2, 2022 | Featured, ICER
On April 13, 2022, ICER released its draft evidence report, “Betibeglogene Autotemcel for Beta Thalassemia.” This document provides a framework for considering what aspects of betibeglogene autotemcel (beti-cel) – a potential curative new gene therapy for beta...
Read more
